Frank Torti, président et président du conseil Vant, a vendu le 19 février 2026 un total de 3 000 000 d'actions de Roivant Sciences pour un montant de 82 039 460 $. Suite au dépôt ...

L’action de Roivant Sciences Ltd a atteint un sommet historique de 27,95$, marquant une étape importante pour cette société biopharmaceutique. L’action se négocie à seulement 1% en dessous de son plus ...

We recently published 10 Easy Double-Digit Gainers. Roivant Sciences Ltd. (NASDAQ:ROIV) was one of the best performers last ...

Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, ...

The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Roivant Sciences Ltd (NASDAQ:ROIV) shares jumped 14.52% in pre-market trading to $24.21 following its February 6, 2026 presentation of Q4 2025 financial results and business updates, despite missing ...

Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is ...

Roivant Sciences Ltd (ROIV) has reached an all-time high, with its stock price climbing to 26.35 USD. This milestone reflects a significant upward trajectory over the past year, with the company’s ...

Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

13:50 Pulmovant annonce la fin du recrutement pour l'étude de phase 2 PHocus sur le mosliciguat chez les patients atteints de maladie pulmonaire interstitielle CI 13:40 Roivant Sciences enregistre une ...